Werth VP, Hejazi E, Pena SM, et al. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis. ACR 2017, abstract 7L.
1 op de 5 axSpA-patiënten voldoet ook aan fibromyalgiecriteria
sep 2017 | Fibromyalgie